KR102417796B1 - 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 - Google Patents

암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 Download PDF

Info

Publication number
KR102417796B1
KR102417796B1 KR1020217011458A KR20217011458A KR102417796B1 KR 102417796 B1 KR102417796 B1 KR 102417796B1 KR 1020217011458 A KR1020217011458 A KR 1020217011458A KR 20217011458 A KR20217011458 A KR 20217011458A KR 102417796 B1 KR102417796 B1 KR 102417796B1
Authority
KR
South Korea
Prior art keywords
cells
cell
acid sequence
nucleic acid
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217011458A
Other languages
English (en)
Korean (ko)
Other versions
KR102417796B9 (ko
KR20210059762A (ko
Inventor
칼 에이치. 준
브루체 엘. 레빈
데이비드 엘. 포터
마이클 디. 카로스
마이클 씨. 밀온
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102417796(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority to KR1020227022607A priority Critical patent/KR20220101745A/ko
Publication of KR20210059762A publication Critical patent/KR20210059762A/ko
Application granted granted Critical
Publication of KR102417796B1 publication Critical patent/KR102417796B1/ko
Publication of KR102417796B9 publication Critical patent/KR102417796B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217011458A 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 Active KR102417796B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227022607A KR20220101745A (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42147010P 2010-12-09 2010-12-09
US61/421470 2010-12-09
US201161502649P 2011-06-29 2011-06-29
US61/502649 2011-06-29
KR1020197038214A KR102243575B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
PCT/US2011/064191 WO2012079000A1 (en) 2010-12-09 2011-12-09 Use of chimeric antigen receptor-modified t cells to treat cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038214A Division KR102243575B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022607A Division KR20220101745A (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도

Publications (3)

Publication Number Publication Date
KR20210059762A KR20210059762A (ko) 2021-05-25
KR102417796B1 true KR102417796B1 (ko) 2022-07-07
KR102417796B9 KR102417796B9 (ko) 2024-03-06

Family

ID=46207528

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217011458A Active KR102417796B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020237030855A Ceased KR20230133410A (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020227022607A Ceased KR20220101745A (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020197038214A Active KR102243575B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020137017546A Active KR102062407B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020237030855A Ceased KR20230133410A (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020227022607A Ceased KR20220101745A (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020197038214A Active KR102243575B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR1020137017546A Active KR102062407B1 (ko) 2010-12-09 2011-12-09 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도

Country Status (43)

Country Link
US (15) US9499629B2 (enExample)
EP (4) EP3305798A1 (enExample)
JP (7) JP5947311B2 (enExample)
KR (5) KR102417796B1 (enExample)
CN (5) CN110452882A (enExample)
AP (1) AP2013006918A0 (enExample)
AU (5) AU2011338200B2 (enExample)
BR (3) BR112013014265B8 (enExample)
CA (1) CA2820681C (enExample)
CL (1) CL2013001645A1 (enExample)
CO (1) CO6801633A2 (enExample)
CR (1) CR20130269A (enExample)
CY (3) CY1119760T1 (enExample)
DK (2) DK2649086T3 (enExample)
DO (1) DOP2013000128A (enExample)
EA (2) EA035484B1 (enExample)
EC (1) ECSP13012739A (enExample)
ES (2) ES2641870T3 (enExample)
FR (1) FR19C1006I2 (enExample)
GT (1) GT201300150A (enExample)
HK (2) HK1243082B (enExample)
HR (2) HRP20171577T1 (enExample)
HU (4) HUE036872T2 (enExample)
IL (1) IL226694B (enExample)
LT (4) LT2649086T (enExample)
LU (1) LUC00104I2 (enExample)
MA (1) MA34813B1 (enExample)
MX (3) MX385933B (enExample)
MY (2) MY169644A (enExample)
NI (1) NI201300051A (enExample)
NL (1) NL300967I2 (enExample)
NO (2) NO2019006I1 (enExample)
NZ (1) NZ612512A (enExample)
PE (1) PE20140178A1 (enExample)
PH (1) PH12013501201A1 (enExample)
PL (2) PL3214091T3 (enExample)
PT (2) PT2649086T (enExample)
RS (2) RS58100B1 (enExample)
SG (2) SG190997A1 (enExample)
SI (2) SI2649086T1 (enExample)
TR (1) TR201820015T4 (enExample)
WO (1) WO2012079000A1 (enExample)
ZA (1) ZA201304470B (enExample)

Families Citing this family (1345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641927B1 (en) 2003-02-18 2015-07-08 Baylor College of Medicine Induced activation in dendritic cells
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
EP2630158B1 (en) 2010-10-22 2018-12-12 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3907297A1 (en) 2011-04-15 2021-11-10 The Johns Hopkins University Safe sequencing system
EP2768863B1 (en) 2011-10-20 2017-09-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd22 chimeric antigen receptors
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
MX2014010185A (es) 2012-02-22 2014-11-14 Univ Pennsylvania Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
RS56443B1 (sr) 2012-02-24 2018-01-31 Abbvie Stemcentrx Llc Ddl3 modulatori i postupci primene
AU2013235726B2 (en) 2012-03-23 2017-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
RU2650805C2 (ru) 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
ES2786263T3 (es) 2012-07-13 2020-10-09 Univ Pennsylvania Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
KR20150030724A (ko) * 2012-07-13 2015-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｃａｒ ｔ 세포를 조절하기 위한 조성물 및 방법
US20160235787A1 (en) * 2012-07-13 2016-08-18 The Trustees Of The University Of Pennsylvania Epitope Spreading Associated with CAR T-Cells
EA201992742A3 (ru) * 2012-07-13 2020-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Применение cart19 для истощения нормальных b-клеток для индукции толерантности
CN111467494B (zh) 2012-07-13 2023-05-02 宾夕法尼亚大学董事会 对cars的抗肿瘤活性的毒性管理
EA028988B1 (ru) * 2012-07-13 2018-01-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ in vitro анализа культуры генетически модифицированных т-клеток для детекции загрязнения
MX380109B (es) * 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
RU2663725C2 (ru) * 2012-09-04 2018-08-08 Селлектис Многоцепочечный химерный антигенный рецептор и его применения
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
US9365641B2 (en) * 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AU2013335180B2 (en) * 2012-10-24 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
US11525163B2 (en) 2012-10-29 2022-12-13 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2015210373B2 (en) * 2012-12-20 2017-04-06 Celgene Corporation Chimeric antigen receptors
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2014214850C1 (en) * 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
KR102064230B1 (ko) 2013-02-15 2020-01-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
UY35340A (es) 2013-02-20 2014-09-30 Novartis Ag Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
EP2958943B1 (en) 2013-02-20 2019-09-11 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
AU2014225788B2 (en) * 2013-03-05 2018-03-29 Baylor College Of Medicine Engager cells for immunotherapy
WO2014151960A2 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
HK1220205A1 (zh) * 2013-03-15 2017-04-28 Celgene Corporation 修饰的t淋巴细胞
CN105247042B (zh) 2013-03-15 2021-06-11 普林斯顿大学理事会 用于高通量纯化的方法和设备
EP4098275A1 (en) 2013-03-15 2022-12-07 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
PT2992020T (pt) * 2013-05-03 2020-02-28 Ohio State Innovation Foundation Células efetoras imunes projetadas específicas do recetor de antígeno quimérico cs1
EP4119662A1 (en) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
MX374681B (es) * 2013-05-13 2025-03-06 Cellectis Receptor quimérico de antígeno específico para cd19 y sus usos.
CN105408473B9 (zh) 2013-05-14 2021-09-17 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
HK1223943A1 (zh) 2013-05-24 2017-08-11 Board Of Regents, The University Of Texas System 嵌合的靶向抗原受体的单克隆抗体
KR20230005422A (ko) 2013-06-10 2023-01-09 다나-파버 캔서 인스티튜트 인크. 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
CN113957061A (zh) 2013-08-30 2022-01-21 得克萨斯大学体系董事会 用于肿瘤疗法的犬尿氨酸耗竭酶的施用
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9765142B2 (en) 2013-10-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services TEM8 antibodies and their use in treatment and detection of tumors
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
WO2015057852A1 (en) * 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
AU2014337195B2 (en) * 2013-10-17 2018-11-08 National University Of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
CN104561069A (zh) * 2013-10-23 2015-04-29 深圳先进技术研究院 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
KR20160084438A (ko) 2013-11-13 2016-07-13 노파르티스 아게 면역 반응을 강화하기 위한 mTOR 억제제
CA2930587A1 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015084513A1 (en) 2013-12-06 2015-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
BR112016014410A2 (pt) 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
PL3083671T3 (pl) 2013-12-20 2021-03-22 Fred Hutchinson Cancer Center Znakowane chimeryczne cząsteczki efektorowe i ich receptory
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3626748A1 (en) * 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10323077B2 (en) * 2014-02-10 2019-06-18 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
WO2015123642A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
PT3105317T (pt) * 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
CN111849912B (zh) * 2014-02-14 2024-03-15 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
WO2015124715A1 (en) * 2014-02-21 2015-08-27 Cellectis Method for in situ inhibition of regulatory t cells
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
CN103820393B (zh) * 2014-02-24 2016-09-07 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
CN104877028A (zh) * 2014-02-28 2015-09-02 百奥迈科生物技术有限公司 抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
DK3241561T3 (da) * 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
PT3119807T (pt) * 2014-03-19 2019-09-04 Cellectis Recetores de antigénios quiméricos específicos de cd123 para imunoterapêutica do cancro
WO2015143224A1 (en) * 2014-03-19 2015-09-24 Ambrx, Inc. Chimeric antigen receptor-modified t-cells
UA125575C2 (uk) 2014-03-21 2022-04-27 Еббві Інк. Кон'югат, що містить антитіло проти egfr та лікарський засіб
US9944702B2 (en) * 2014-04-03 2018-04-17 Cellectis CD33 specific chimeric antigen receptors for cancer immunotherapy
EP4406610A3 (en) * 2014-04-07 2024-10-30 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
RU2016143389A (ru) 2014-04-10 2018-05-15 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
MX382541B (es) 2014-04-23 2025-03-13 Juno Therapeutics Inc Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
RS60106B1 (sr) * 2014-04-25 2020-05-29 Bluebird Bio Inc Mnd promoterni himerni antigenski receptori
EP3134095B1 (en) * 2014-04-25 2020-04-22 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
EP3134434A4 (en) * 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
GB2540694A (en) * 2014-04-29 2017-01-25 Seattle Children's Hospital (Dba Seattle Children's Res Institute) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015168469A1 (en) 2014-05-02 2015-11-05 Emory University Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto
US10301370B2 (en) 2014-05-02 2019-05-28 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor T cells
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
DE112014006656B4 (de) 2014-05-14 2018-05-17 Carsgen Therapeutics Limited Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins
SG11201609118RA (en) 2014-05-15 2016-11-29 Univ Singapore Modified natural killer cells and uses thereof
US11041021B2 (en) 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
CN106536564B (zh) 2014-06-02 2021-08-31 美国卫生和人力服务部 靶向cd-19的嵌合抗原受体
CN111394317B (zh) 2014-06-06 2024-07-12 2赛文缇生物公司 改善的t细胞组合物
AU2015276131A1 (en) * 2014-06-17 2016-11-17 Cellectis CD123 specific multi-chain chimeric antigen receptor
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CN107075483A (zh) 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 用于过继细胞治疗的工程改造的细胞
MX390943B (es) * 2014-07-21 2025-03-21 Novartis Ag Receptores de antígeno quimérico cd33 y usos de los mismos.
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US10568947B2 (en) * 2014-07-21 2020-02-25 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
MX367787B (es) * 2014-07-29 2019-09-06 Cellectis Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
WO2016016341A1 (en) * 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016033329A1 (en) 2014-08-27 2016-03-03 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
EP2990416B1 (en) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
EP3699188A1 (en) * 2014-09-04 2020-08-26 Cellectis 5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
SG11201701775VA (en) * 2014-09-09 2017-04-27 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
JP6839074B2 (ja) * 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
WO2016044383A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
ES2738705T3 (es) * 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
HUE054673T2 (hu) * 2014-10-02 2021-09-28 Wistar Inst Rák kezelésére szolgáló eljárások és készítmények
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
EP3204491A1 (en) * 2014-10-07 2017-08-16 Cellectis Method for modulating car-induced immune cells activity
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
HUE060047T2 (hu) 2014-10-09 2023-01-28 Univ Yamaguchi CAR expressziós vektor és CAR-t expresszáló T-sejtek
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
AU2015336029B2 (en) 2014-10-20 2021-07-22 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
BR112017008693A2 (pt) 2014-10-31 2018-02-27 The Trustees Of The University Of Pennsylvania célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
AU2015339106B2 (en) * 2014-10-31 2020-07-02 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding T cells
US20170363629A1 (en) * 2014-11-05 2017-12-21 Board Of Regents, The University Of Texas System Biomarkers and targets for cancer immunotherapy
PL3757206T3 (pl) 2014-11-05 2024-07-08 Juno Therapeutics, Inc. Sposoby transdukcji i przetwarzania komórek
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN105601746B (zh) * 2014-11-21 2021-02-19 三生国健药业（上海）股份有限公司 一种嵌合Fc受体的融合蛋白及其制备方法和应用
US11266739B2 (en) * 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
AU2015357485B2 (en) 2014-12-05 2020-10-15 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
CN113968913A (zh) * 2014-12-08 2022-01-25 美国卫生和人力服务部 抗cd70嵌合抗原受体
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
SG10202013144UA (en) 2014-12-12 2021-02-25 Bluebird Bio Inc Bcma chimeric antigen receptors
EP3240805B1 (en) 2014-12-15 2024-11-27 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
KR102376242B1 (ko) * 2014-12-24 2022-03-21 오토러스 리미티드 세포
KR20250075716A (ko) 2014-12-29 2025-05-28 노파르티스 아게 키메라 항원 수용체-발현 세포를 제조하는 방법
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
CN107406516B (zh) 2015-01-26 2021-11-23 塞勒克提斯公司 用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR)
JP6849600B6 (ja) * 2015-01-29 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ キメラ抗原受容体、組成物及び方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP4134430A1 (en) 2015-02-06 2023-02-15 National University of Singapore Methods for enhancing efficacy of therapeutic immune cells
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
US20160228544A1 (en) * 2015-02-11 2016-08-11 Ensysce Biosciences, Inc. Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
EP3259352A4 (en) * 2015-02-19 2018-12-05 University of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
US10973914B2 (en) 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
CN107667169B (zh) 2015-02-24 2021-10-29 得克萨斯州大学系统董事会 遗传修饰的t细胞的选择方法
JP6784687B2 (ja) 2015-02-24 2020-11-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結合誘発型転写スイッチ及びその使用方法
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US10195272B2 (en) 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
EP3089761B1 (en) * 2015-03-02 2019-06-12 Innovative Cellular Therapeutics Co., Ltd. Reducing immune tolerance induced by pd l1
HK1246317A1 (zh) * 2015-03-05 2018-09-07 Fred Hutchinson Cancer Center 免疫调节融合蛋白及其用途
EP3268087A4 (en) 2015-03-12 2018-08-29 The Regents of the University of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
EP3270936A4 (en) * 2015-03-17 2018-08-08 Chimera Bioengineering Inc. Smart car devices, de car polypeptides, side cars and uses thereof
WO2016149578A1 (en) 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
AU2016235541B2 (en) 2015-03-20 2021-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
AU2016243128A1 (en) * 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
AU2016243124A1 (en) 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
CA2981304C (en) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
US20180208658A1 (en) 2015-04-03 2018-07-26 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
EP3280437A4 (en) 2015-04-06 2018-09-12 Jianhua Yu Egfr-directed car therapy for glioblastoma
DK3280432T3 (da) 2015-04-06 2021-04-26 Subdomain Llc Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
HUE059218T2 (hu) * 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3288638A1 (en) 2015-04-25 2018-03-07 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
EP3288569A4 (en) * 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
JP2018518459A (ja) * 2015-04-30 2018-07-12 ユニバーシティ オブ サザン カリフォルニア 分泌性ｔｎｔ ｃａｒ細胞免疫療法
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
AU2016257721B2 (en) 2015-05-01 2019-11-14 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
JP2018515138A (ja) 2015-05-06 2018-06-14 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 微生物集団の改変および微生物相の修飾
AU2016261600B2 (en) 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
US11253616B2 (en) 2017-09-06 2022-02-22 The Trustees Of The University Of Pennsylvania Small molecules for dual function positron emission tomography (PET) and cell suicide switches
US20200316231A1 (en) * 2015-05-10 2020-10-08 The Trustees Of The University Of Pennsylvania Compositions And Methods For Imaging Immune Cells
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
CN108137669B (zh) * 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
EP3298046B1 (en) * 2015-05-20 2025-02-12 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
BR112017024797A2 (pt) 2015-05-20 2018-08-07 The Broad Institute Inc. neoantígenos partilhados
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
IL316196A (en) * 2015-05-28 2024-12-01 Us Health Methods of conditioning patients for t cell therapy
HK1248137A1 (zh) * 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
BR122023022076A2 (pt) 2015-05-28 2024-01-16 Kite Pharma, Inc. Agente pré-condicionantes, seus usos e métodos para identificar uma dose de um ou mais agentes de pré-condicionamento e para verificar a eficácia dos mesmos
US20180161369A1 (en) 2015-05-29 2018-06-14 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CN107847601A (zh) * 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
WO2016196957A1 (en) * 2015-06-05 2016-12-08 Novartis Ag Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
AU2016274767B2 (en) 2015-06-09 2022-05-19 Eureka Therapeutics, Inc. T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
CA2987290C (en) 2015-06-10 2023-10-03 Nantkwest, Inc. Modified nk-92 cells for treating cancer
WO2016201225A1 (en) 2015-06-11 2016-12-15 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
CN105177031B (zh) * 2015-06-12 2018-04-24 北京艺妙神州医疗科技有限公司 嵌合抗原受体修饰的t细胞及其用途
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
CA2989949A1 (en) * 2015-06-19 2016-12-22 Sebastian KOBOLD Pd-1-cd28 fusion proteins and their use in medicine
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
MA42902A (fr) * 2015-07-08 2018-05-16 Univ Johns Hopkins Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
US11116795B2 (en) * 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
WO2018126369A1 (en) 2017-01-05 2018-07-12 Shanghai Sidansai Biotechnology Co., Ltd Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
CN108025024B (zh) 2015-07-28 2022-11-29 宾夕法尼亚大学董事会 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
EP3575403A1 (en) 2015-08-05 2019-12-04 Yoo Young Pharm Co., Ltd. Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CN106467906B (zh) * 2015-08-20 2019-09-27 北京马力喏生物科技有限公司 构建体、转基因淋巴细胞及其制备方法和用途
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
EP3340995A4 (en) * 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE
US11649435B2 (en) * 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN108136014A (zh) * 2015-08-31 2018-06-08 蓝鸟生物公司 抗唾液酸tn嵌合抗原受体
EP3344996A2 (en) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
CN108350462B (zh) * 2015-09-11 2022-05-27 生物权威（英国）有限公司 嵌合抗原受体及其用途
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US20180273897A1 (en) * 2015-09-18 2018-09-27 The General Hospital Corporation Modified t-cells having anti-fugetactic properties and uses thereof
US11890348B2 (en) 2015-09-18 2024-02-06 The General Hospital Corporation Localized delivery of anti-fugetactic agent for treatment of cancer
US10738099B2 (en) * 2015-09-22 2020-08-11 The Trustees Of The University Of Pennsylvania Method of redirecting T cells to treat HIV infection
EP3352791B1 (en) 2015-09-24 2019-10-30 AbVitro LLC Hiv antibody compositions and methods of use
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
EP3355937A4 (en) 2015-09-28 2019-04-17 Regents of the University of Minnesota CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
RU2759879C2 (ru) * 2015-10-06 2021-11-18 Сити Оф Хоуп Химерные рецепторы антигена, нацеленные на psca
US10392441B2 (en) 2015-10-07 2019-08-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
EP3359650A4 (en) 2015-10-08 2019-03-20 Innovative Cellular Therapeutics Co., Ltd. ACTIVATION AND EXPANSION OF CELLS
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP6821688B2 (ja) 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． キメラ抗原受容体および使用方法
US11756655B2 (en) * 2015-10-09 2023-09-12 Guardant Health, Inc. Population based treatment recommender using cell free DNA
CN105924530B (zh) * 2015-10-13 2019-08-06 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
CN106755023A (zh) * 2015-10-15 2017-05-31 中国人民解放军军事医学科学院附属医院 带安全开关的嵌合抗原受体免疫细胞及其制备方法与应用
EP4265633A3 (en) 2015-10-16 2024-01-24 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
EP3362569B1 (en) 2015-10-16 2021-09-01 Ludwig-Maximilians-Universität München Cxcr6-transduced t cells for targeted tumor therapy
CN108601850A (zh) 2015-10-19 2018-09-28 马萨诸塞大学 抗癌和抗炎症治疗及其方法
WO2017070395A1 (en) 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN105132445B (zh) * 2015-10-23 2018-10-02 马健颖 一种特异识别肿瘤细胞的受体蛋白、t淋巴细胞及nk细胞
EP3365016A4 (en) * 2015-10-23 2019-07-17 Sorrento Therapeutics, Inc. PROGRAMMABLE UNIVERSAL CELL RECEPTORS AND METHOD FOR USE THEREOF
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MA44314A (fr) * 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN105384826A (zh) * 2015-11-19 2016-03-09 广州熙帝生物科技有限公司 表达嵌合抗原受体的脐血有核细胞及其应用
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
JP6976960B2 (ja) * 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
MA43378A (fr) 2015-12-03 2018-10-10 Juno Therapeutics Inc Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
MA43377A (fr) 2015-12-04 2021-05-19 Hutchinson Fred Cancer Res Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
EP3384013A4 (en) * 2015-12-04 2019-07-10 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNOTOLERANCE
BR112018011089A2 (pt) 2015-12-04 2018-12-04 Intellia Therapeutics Inc composições e métodos para a imuno-oncologia
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
EP3397755B1 (en) 2015-12-28 2024-11-06 Novartis AG Methods of making chimeric antigen receptor -expressing cells
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
EP3399991A4 (en) 2016-01-08 2019-08-07 The Regents of The University of California REQUIRES ACTIVE HETERODIMER POLYPEPTIDES AND METHOD FOR USE THEREOF
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
JP7022067B2 (ja) * 2016-01-14 2022-02-17 メモリアル スローン ケタリング キャンサー センター Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
EP3402509A4 (en) * 2016-01-14 2019-07-10 Seattle Children's Hospital (DBA Seattle Children's Research Institute) TUMOR SPECIFIC IFNA SECRETION BY CAR T CELLS FOR RESTORING SOLID TUMOR MICRO ENVIRONMENT
US11382886B2 (en) 2016-01-15 2022-07-12 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
TWI657096B (zh) 2016-01-21 2019-04-21 輝瑞股份有限公司 對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
CN105567640A (zh) * 2016-01-27 2016-05-11 苏州佰通生物科技有限公司 一种嵌合抗原受体脂肪干细胞及其制备方法
JP2019509275A (ja) 2016-02-23 2019-04-04 イミューン デザイン コーポレイション マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
JP2019513347A (ja) 2016-03-04 2019-05-30 ノバルティス アーゲー 複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
JP6963560B2 (ja) * 2016-03-14 2021-11-10 ウィスコンシン アラムニ リサーチ ファンデーション Ｔ細胞の拡張及び活性化の方法
US20190355459A1 (en) 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
EP3430548A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
CN109153989B (zh) * 2016-03-17 2022-10-28 国立大学法人山口大学 表达免疫功能调控因子的免疫活性细胞及表达载体
KR102366611B1 (ko) 2016-03-18 2022-02-23 프레드 헛친슨 켄서 리서치 센터 Cd20 면역요법을 위한 조성물 및 방법
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
BR112018069251A2 (pt) 2016-03-22 2019-01-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) métodos de intervenção precoce para prevenir ou melhorar a toxicidade
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
WO2017167217A1 (en) * 2016-04-01 2017-10-05 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
MA44507A (fr) 2016-04-01 2019-02-06 Amgen Inc Récepteurs chimères de flt3 et leurs procédés d'utilisation
PE20200400A1 (es) 2016-04-01 2020-02-26 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos
SG10201912489QA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6987390B2 (ja) 2016-04-08 2021-12-22 エモリー ユニバーシティー 細胞ベースの治療法を用いて癌および感染性疾患を処置する方法
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN106399255B (zh) * 2016-04-13 2019-10-18 阿思科力(苏州)生物科技有限公司 Pd-1 car-t细胞及其制备方法和应用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
IL312206A (en) 2016-04-15 2024-06-01 Novartis Ag Preparations and methods for selective protein expression
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
CN105907719B (zh) * 2016-04-18 2019-10-18 阿思科力(苏州)生物科技有限公司 Anti ROBO1 CAR-T细胞及其制备和应用
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2018018958A1 (en) * 2016-04-22 2018-02-01 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
EP3452499A2 (en) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
US11261223B2 (en) 2016-05-11 2022-03-01 The University Of Chicago Methods of treating cancers with CT45 targeted therapies
JP2019521659A (ja) 2016-05-27 2019-08-08 アーディジェン， エルエルシー ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子
EP4413999A3 (en) * 2016-05-27 2024-08-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Flt3-specific chimeric antigen receptors and methods using same
CN105837693A (zh) * 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
JP2019517518A (ja) 2016-06-03 2019-06-24 メモリアル スローン ケタリング キャンサー センター 早期治療選択肢としての養子細胞療法
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2017213979A1 (en) * 2016-06-06 2017-12-14 St. Jude Children's Research Hospital Anti-cd7 chimeric antigen receptor and method of use thereof
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
SG11201811193TA (en) 2016-06-08 2019-01-30 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
EP3468599A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214462A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468994A1 (en) 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
CN107523545A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN106117367B (zh) * 2016-06-24 2020-02-11 安徽未名细胞治疗有限公司 一种her-3特异性嵌合抗原受体及其应用
EP4353750A3 (en) 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP6987134B2 (ja) 2016-06-27 2021-12-22 ジュノー セラピューティクス インコーポレイテッド ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
WO2018002358A1 (en) 2016-06-30 2018-01-04 F. Hoffmann-La Roche Ag Improved adoptive t-cell therapy
TWI691510B (zh) 2016-07-12 2020-04-21 美商凱特製藥公司 抗原結合分子和使用彼之方法
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
WO2018013975A1 (en) 2016-07-15 2018-01-18 Viracta Therapeutics, Inc. Hdac inhibitors for use with nk cell based therapies
JP7219376B2 (ja) 2016-07-15 2023-02-08 ノバルティス アーゲー キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
CA3031289A1 (en) * 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells to treat cancer
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US20190151365A1 (en) 2016-07-28 2019-05-23 Novartis Ag Combination therapies of chimeric antigen receptors and pd-1 inhibitors
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11421287B2 (en) 2016-07-29 2022-08-23 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
CN110087672A (zh) 2016-07-29 2019-08-02 朱诺治疗学股份有限公司 免疫调节多肽及相关组合物和方法
MX2019001184A (es) * 2016-07-29 2019-09-26 Juno Therapeutics Inc Anticuerpos anti-idiotípicos y métodos relacionados.
BR112019002035A2 (pt) 2016-08-01 2019-05-14 Novartis Ag tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
CN112481217A (zh) 2016-09-01 2021-03-12 嵌合体生物工程公司 Gold优化的car t-细胞
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
CN117298260A (zh) 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
MA46194A (fr) 2016-09-12 2019-07-17 Juno Therapeutics Inc Ensembles de poches de bioréacteur de perfusion
WO2018057585A1 (en) 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
CA3037528A1 (en) * 2016-09-23 2018-03-29 University Of Southern California Chimeric antigen receptors and compositions and methods of use thereof
EP4353319A3 (en) 2016-09-28 2024-06-05 Atossa Therapeutics, Inc. Methods of adoptive cell therapy
WO2018064205A1 (en) 2016-09-28 2018-04-05 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
CA3037086A1 (en) 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN107151654B (zh) * 2016-10-11 2020-05-05 深圳宾德生物技术有限公司 一种人源t淋巴细胞的培养基及其制备方法和应用
CA3037387A1 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CN107936120B (zh) * 2016-10-13 2021-03-09 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
JP7149935B2 (ja) 2016-10-19 2022-10-07 ザ スクリプス リサーチ インスティテュート ヒト化された標的化部分および／または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
EP4092049A1 (en) 2016-10-20 2022-11-23 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
US20200040059A1 (en) 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CN110139669A (zh) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2017363278B2 (en) * 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
CA3040533A1 (en) * 2016-12-02 2018-06-07 Cartesian Therapeutics, Inc. Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
CA3045355A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
US20190350978A1 (en) 2016-12-05 2019-11-21 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN108165568B (zh) * 2016-12-07 2020-12-08 上海恒润达生生物科技有限公司 一种培养CD19CAR-iNKT细胞方法及用途
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
MX2019006631A (es) 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
CN108218994A (zh) * 2016-12-14 2018-06-29 上海恒润达生生物科技有限公司 一种方法培养t记忆干细胞
EP3555273B1 (en) 2016-12-16 2024-05-22 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
US11447562B2 (en) 2017-01-01 2022-09-20 Chi-Yu Gregory Lee RP215 chimeric antigen receptor construct and methods of making and using same
US11566061B2 (en) 2017-01-05 2023-01-31 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
JP7780248B2 (ja) 2017-01-06 2025-12-04 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CN108285920A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 一种体内检测cart细胞表达的技术及其用途
JP7429338B2 (ja) 2017-01-10 2024-02-08 ジュノー セラピューティクス インコーポレイテッド 細胞療法および関連方法のエピジェネティック解析
GB201700553D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
EP3568416A4 (en) * 2017-01-13 2020-07-08 Celdara Medical, LLC TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
AU2018209400B2 (en) 2017-01-20 2022-06-02 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN108342363B (zh) * 2017-01-25 2021-02-12 北京马力喏生物科技有限公司 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
RU2674894C2 (ru) * 2017-01-30 2018-12-13 Общество с ограниченной ответственностью "ПЛАНТА" Новые люциферазы и способы их использования
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018144597A1 (en) * 2017-01-31 2018-08-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of sensitizing cancer cells to immune cell killing
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
EP4287191A3 (en) 2017-02-12 2024-03-06 BioNTech US Inc. Hla-based methods and compositions and uses thereof
TW202344517A (zh) 2017-02-14 2023-11-16 美商凱特製藥公司 Ｃｄ７０結合分子及使用彼之方法
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018157072A1 (en) 2017-02-27 2018-08-30 Life Technologies Corporation Expansion of populations of t cells by the use of modified serum free media
JP7228522B2 (ja) 2017-02-27 2023-02-24 ジュノー セラピューティクス インコーポレイテッド 細胞療法における投薬に関する組成物、製造物品、および方法
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CN110913903B (zh) 2017-03-03 2024-03-01 思进股份有限公司 聚糖相互作用化合物和使用方法
WO2018161017A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Cd19 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
AU2018234640C9 (en) 2017-03-14 2024-10-03 Juno Therapeutics, Inc. Methods for cryogenic storage
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
KR20240123406A (ko) 2017-03-16 2024-08-13 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
JP2020513832A (ja) 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
JP7137896B2 (ja) * 2017-03-24 2022-09-15 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CN110636851B (zh) 2017-03-27 2023-11-03 新加坡国立大学 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途
CN118161496A (zh) 2017-03-31 2024-06-11 小利兰·斯坦福大学托管委员会 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
IL269209B2 (en) 2017-04-01 2023-11-01 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
EP3655022A1 (en) 2017-04-03 2020-05-27 Kite Pharma, Inc. Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
JP7284707B2 (ja) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
US11796534B2 (en) 2017-04-14 2023-10-24 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
AU2018251187B2 (en) 2017-04-14 2024-03-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
CN108727497A (zh) * 2017-04-17 2018-11-02 沈阳美达博生物科技有限公司 一种cd19抗体及其应用
EP3612629A1 (en) 2017-04-18 2020-02-26 The Broad Institute, Inc. Compositions for detecting secretion and methods of use
CA3058779A1 (en) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
ES3038614T3 (en) 2017-04-27 2025-10-14 Juno Therapeutics Inc Oligomeric particle reagents and methods of use thereof
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018204427A1 (en) 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN107226867B (zh) * 2017-07-25 2018-02-06 重庆精准生物技术有限公司 抗人cd19抗原的嵌合抗原受体及其应用
DE112018002302B4 (de) * 2017-05-02 2020-10-22 Chongqing Precision Biotech Company Limited Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
AU2018266202C1 (en) * 2017-05-10 2025-05-08 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
US11622977B2 (en) 2017-05-12 2023-04-11 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CA3062433A1 (en) 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
US12297436B2 (en) 2017-05-18 2025-05-13 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2018218072A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
EP3406733A1 (en) 2017-05-24 2018-11-28 SIB Swiss Institute of Bioinformatics Kinase mutants and uses thereof
JP7187486B2 (ja) 2017-05-25 2022-12-12 レイドス， インコーポレイテッド Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド
NZ759234A (en) 2017-05-26 2022-12-23 Kite Pharma Inc Methods of making and using embryonic mesenchymal progenitor cells
US11566223B2 (en) 2017-06-01 2023-01-31 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cell preparation and uses thereof
EP3631805A4 (en) * 2017-06-02 2021-03-24 Mayo Foundation for Medical Education and Research SYSTEM AND METHOD FOR PROVIDING EXPERTISE FROM CLINICAL RESULTS IN DISEASE TREATMENT
AU2018275891B2 (en) 2017-06-02 2025-02-27 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
BR112019024291A2 (pt) 2017-06-09 2020-07-28 Providence Health & Services-Oregon utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
PT3538645T (pt) 2017-06-20 2021-04-15 Inst Curie Células imunológicas deficitárias em suv39h1
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
US10233226B2 (en) 2017-06-21 2019-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
CA3068286A1 (en) 2017-06-22 2018-12-27 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
BR112019027104A2 (pt) 2017-06-22 2020-08-18 Novartis Ag moléculas de anticorpo para cd73 e usos das mesmas
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019002633A1 (en) 2017-06-30 2019-01-03 Cellectis CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
CN107287164A (zh) * 2017-07-07 2017-10-24 青岛协和华美医学诊断技术有限公司 靶向cd19的嵌合抗原受体t细胞、制备方法及应用
US12065474B2 (en) 2017-07-07 2024-08-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 costimulatory domains
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
AU2018304173A1 (en) * 2017-07-17 2020-01-30 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
AU2018310452A1 (en) 2017-07-29 2020-02-13 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
CN111183156A (zh) 2017-07-31 2020-05-19 莱蒂恩技术公司 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法
US12485102B2 (en) 2017-08-02 2025-12-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
US12241081B2 (en) 2017-08-03 2025-03-04 The Scripps Research Institute B cell receptor modification in B cells
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
SG11202001010UA (en) 2017-08-07 2020-03-30 Univ Johns Hopkins Methods and materials for assessing and treating cancer
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
MA49981A (fr) 2017-08-09 2020-06-17 Juno Therapeutics Inc Procédés et compositions de préparation de cellules génétiquement modifiées
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
JP7269917B2 (ja) 2017-08-17 2023-05-09 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
CA3074495A1 (en) * 2017-09-01 2019-03-07 Gpb Scientific, Llc Methods for preparing therapeutically active cells using microfluidics
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CN107557337B (zh) * 2017-09-15 2020-06-26 山东兴瑞生物科技有限公司 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
WO2019055853A1 (en) 2017-09-15 2019-03-21 Life Technologies Corporation COMPOSITIONS AND METHODS FOR CELL CULTURE AND EXPANSION
EP3681531A1 (en) 2017-09-15 2020-07-22 Kite Pharma, Inc. Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
IL273402B2 (en) 2017-09-19 2025-01-01 Univ British Columbia Antibodies against human leukocyte antigens type A2 and methods of using them
EP3684408A1 (en) 2017-09-19 2020-07-29 Massachusetts Institute of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
CA3076547A1 (en) 2017-09-20 2019-03-28 The University Of British Columbia Novel anti-hla-a2 antibodies and uses thereof
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
US10844371B2 (en) 2017-09-22 2020-11-24 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
EP3684816B1 (en) 2017-09-22 2024-05-29 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein degraders and uses thereof
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
CN111433354A (zh) * 2017-09-26 2020-07-17 朗沃德大学 作为免疫疗法的pd1特异性嵌合抗原受体
CN109554349B (zh) * 2017-09-27 2022-06-24 亘喜生物科技（上海）有限公司 Pd-1基因表达沉默的工程化免疫细胞
US20200306303A1 (en) * 2017-09-29 2020-10-01 Chiou Hwa YUH Methods and compositions enhancing survival and functionality of anti-tumor and anti-viral t cells
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AU2018345539A1 (en) 2017-10-03 2020-04-16 Editas Medicine, Inc. HPV-specific binding molecules
WO2019074892A1 (en) 2017-10-09 2019-04-18 Wisconsin Alumni Research Foundation ANTIBODIES TARGETING GLIOBLASTOME STRAIN TYPE CELLS AND METHODS OF USE
CN111801347A (zh) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
TW202510896A (zh) 2017-10-18 2025-03-16 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
CN109694854B (zh) * 2017-10-20 2023-11-21 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
EP3700932A1 (en) 2017-10-27 2020-09-02 Kite Pharma, Inc. T cell receptor antigen binding molecules and methods of use thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
CN111527209B (zh) 2017-11-01 2024-11-12 爱迪塔斯医药股份有限公司 Crispr-cas9编辑t细胞中的tgfbr2以用于免疫疗法的方法、组合物和组分
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
CN111741757B (zh) * 2017-11-03 2023-12-19 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
CN111565742B (zh) 2017-11-04 2024-03-01 艾拉维弗生物制品公司 使用axl诱骗受体治疗转移性癌症的方法
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
KR20200079312A (ko) 2017-11-06 2020-07-02 에디타스 메디신, 인코포레이티드 면역요법을 위한 t 세포 내 cblb의 crispr-cas9 편집 방법, 조성물 및 성분
EP3707165A4 (en) * 2017-11-07 2021-09-08 The Board of Regents of The University of Texas System TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN CANCER TREATMENT
EP3706904A1 (en) 2017-11-10 2020-09-16 Juno Therapeutics, Inc. Closed-system cryogenic vessels
EP3707160A1 (en) 2017-11-10 2020-09-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting tumor antigens
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
US11377482B2 (en) 2017-11-14 2022-07-05 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
CN111787938A (zh) 2017-11-15 2020-10-16 诺华股份有限公司 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN109837244A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用
BR112020010579A2 (pt) 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
WO2019112978A2 (en) * 2017-12-04 2019-06-13 Coare Biotechnology, Inc. Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
MX2020005908A (es) 2017-12-08 2020-10-07 Juno Therapeutics Inc Proceso para producir una composicion de celulas t modificadas.
MX2020005906A (es) 2017-12-08 2020-10-22 Juno Therapeutics Inc Marcadores fenotipicos para terapia celular y metodos relacionados.
EP3724327A4 (en) 2017-12-14 2022-01-12 EZY Biotech LLC SUBJECT-SPECIFIC TUMOR INHIBITION CELLS AND THEIR USE
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
US11661439B2 (en) 2017-12-17 2023-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
CN108018312B (zh) * 2017-12-20 2019-09-10 上海优卡迪生物医药科技有限公司 一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN109970864A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 一种双向激活共刺激分子受体及其用途
CN109970866B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd28双向激活共刺激分子受体及其用途
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019134036A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019136288A1 (en) * 2018-01-05 2019-07-11 Maxcyte, Inc. Chronic car treatment for cancer
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN112088008B (zh) * 2018-01-11 2024-01-02 浙江煦顼技术有限公司 修饰细胞的扩增及其用途
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20210023134A1 (en) 2018-01-15 2021-01-28 Pfizer Inc. Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
BR112020015328A2 (pt) 2018-01-29 2020-12-08 Merck Patent Gmbh Inibidores de gcn2 e usos dos mesmos
CA3089769A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
KR102115236B1 (ko) * 2018-01-29 2020-05-27 (주)에스엠티바이오 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
JP2021511802A (ja) 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬
US12338459B2 (en) 2018-02-02 2025-06-24 Arizona Board Of Regents On Behalf Of Arizona State University DNA-chimeric antigen receptor T cells for immunotherapy
BR112020015884A2 (pt) 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
US20210087511A1 (en) * 2018-02-09 2021-03-25 Global Life Sciences Solutions Usa Llc Bioprocessing methods for cell therapy
CA3089170A1 (en) 2018-02-09 2019-08-15 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019154313A1 (zh) 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110157677A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
EP3752531A1 (en) 2018-02-14 2020-12-23 Kite Pharma, Inc. Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
CN112534044A (zh) 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
US20210137839A1 (en) 2018-02-17 2021-05-13 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
BR112020014576A2 (pt) 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
KR20200130709A (ko) 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
WO2019170845A1 (en) 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
CA3093915A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CA3095027A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
AU2019251473A1 (en) 2018-04-10 2020-10-22 Amgen Inc. Chimeric receptors to DLL3 and methods of use thereof
AU2019252944B2 (en) 2018-04-12 2022-12-08 Kite Pharma, Inc. Chimeric receptor T cell treatment using characteristics of the tumor microenvironment
US20210155986A1 (en) 2018-04-13 2021-05-27 The Johns Hopkins University Non-invasive detection of response to immunotherapy
BR112020020919A2 (pt) 2018-04-13 2021-04-06 Sangamo Therapeutics France Receptor de antígeno quimérico específico para receptor de interleucina-23
WO2019200250A1 (en) 2018-04-13 2019-10-17 Velculescu Victor E Non-invasive detection of response to a targeted therapy
KR102862473B1 (ko) 2018-04-16 2025-09-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 인간 키누레니나제 효소 및 이의 사용법
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7527641B2 (ja) 2018-04-18 2024-08-05 アブクロン・インコーポレイテッド スイッチ分子及びスイッチャブルキメラ抗原受容体
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019204496A1 (en) * 2018-04-19 2019-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating melanoma with a chimeric antigen receptor
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof
US11059826B2 (en) 2018-04-24 2021-07-13 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
KR102806143B1 (ko) * 2018-05-01 2025-05-14 프레드 허친슨 캔서 센터 유전자 발현을 위한 나노입자 및 이의 용도
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN112312930A (zh) * 2018-05-02 2021-02-02 宾夕法尼亚大学董事会 磷脂酶a2受体嵌合自身抗体受体t细胞的组合物和方法
CN108753774B (zh) * 2018-05-03 2021-03-30 山东省齐鲁细胞治疗工程技术有限公司 干扰il-6表达的cd19-car-t细胞及其应用
WO2019213184A1 (en) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
CN112424342A (zh) 2018-05-08 2021-02-26 生命科技公司 用于培养和扩增细胞的组合物和方法
IL278348B2 (en) 2018-05-11 2025-03-01 Crispr Therapeutics Ag Methods and preparations for treating cancer
MY198871A (en) 2018-05-14 2023-10-02 Gilead Sciences Inc Mcl-1 inhibitors
KR20210045953A (ko) 2018-05-18 2021-04-27 더 존스 홉킨스 유니버시티 암의 평가 및/또는 치료를 위한 무 세포 dna
CA3100386A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CN108715859B (zh) * 2018-05-31 2021-08-03 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd22的嵌合抗原受体及其应用
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
KR20230093066A (ko) 2018-06-01 2023-06-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
JP7411578B2 (ja) * 2018-06-01 2024-01-11 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 癌を治療するための物質及び方法
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
MY208825A (en) 2018-06-13 2025-05-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
KR20190141511A (ko) * 2018-06-14 2019-12-24 주식회사 녹십자랩셀 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
AU2019288669B2 (en) 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
EP3810780A1 (en) 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
CA3104862A1 (en) 2018-07-03 2020-01-09 Sotio, LLC Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102625712B1 (ko) 2018-07-13 2024-01-19 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2020017479A1 (ja) 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
US20210277148A1 (en) 2018-07-18 2021-09-09 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
DK4324851T3 (da) 2018-07-19 2025-10-06 Regeneron Pharma Kimæriske antigenreceptorer med BCMA-specificitet og anvendelser deraf
CN108949759B (zh) * 2018-07-23 2021-06-01 合肥一兮生物科技有限公司 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
JP2021532116A (ja) 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
CN112533953A (zh) 2018-08-02 2021-03-19 凯德药业股份有限公司 嵌合抗原受体疗法t细胞扩增动力学及其用途
BR112021002245A2 (pt) 2018-08-09 2021-05-04 Juno Therapeutics Inc métodos para avaliar ácidos nucleicos integrados
MX2021001523A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
CA3109209A1 (en) * 2018-08-10 2020-02-13 Eutilex Co., Ltd. Chimeric antigen receptor that binds hla-dr and car-t cell
SG11202101284UA (en) 2018-08-14 2021-03-30 Sotio Llc Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
CN110856724B (zh) 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
MX2021002415A (es) 2018-08-28 2021-09-21 Vor Biopharma Inc Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
EP3844266A1 (en) 2018-08-28 2021-07-07 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CA3110096A1 (en) 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
DK3844267T3 (da) 2018-08-31 2025-09-22 Novartis Ag Fremgangsmåder til fremstilling af kimære antigenreceptorudtrykkende celler
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
US12366580B2 (en) 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
MA53651A (fr) 2018-09-19 2021-07-28 Alpine Immune Sciences Inc Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées
EP3856777A1 (en) 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
JP7557882B2 (ja) 2018-09-28 2024-09-30 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
JP7687952B2 (ja) 2018-10-01 2025-06-03 アディセット セラピューティクス， インク． 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
MX2021004588A (es) 2018-10-22 2022-01-18 Shanghai Genbase Biotechnology Co Ltd Anticuerpo anti-cldn18.2 y sus usos.
EP3870602A1 (en) 2018-10-23 2021-09-01 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020086989A1 (en) * 2018-10-25 2020-04-30 Innovative Cellular Therapeutics CO., LTD. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US20220002669A1 (en) 2018-10-31 2022-01-06 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020097132A1 (en) 2018-11-06 2020-05-14 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
WO2020097346A1 (en) * 2018-11-07 2020-05-14 Unum Therapeutics Inc. ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
CN109467604A (zh) * 2018-11-07 2019-03-15 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-CD19scFv-TREM1及其用途
CN109503717A (zh) * 2018-11-07 2019-03-22 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-CD19scfv-NKp44及其用途
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
JP2022507453A (ja) 2018-11-14 2022-01-18 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Ｔ細胞送達のためのフソソーム組成物
SG11202105084VA (en) 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
SG11202105173VA (en) * 2018-11-20 2021-06-29 Innovative Cellular Therapeutics Holdings Ltd Modified cell expressing therapeutic agent and uses thereof
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
EP3887518A2 (en) 2018-11-28 2021-10-06 Board of Regents, The University of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
US20220033778A1 (en) 2018-11-29 2022-02-03 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
DK3886894T3 (da) 2018-11-30 2024-06-03 Juno Therapeutics Inc Fremgangsmåder til dosering og behandling af b-cellemaligniteter i adoptiv celleterapi
ES2981569T3 (es) 2018-11-30 2024-10-09 Juno Therapeutics Inc Métodos de tratamiento usando terapia celular adoptiva
KR102891608B1 (ko) 2018-11-30 2025-11-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
EP3891185A2 (en) 2018-12-05 2021-10-13 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
CN118931967A (zh) * 2018-12-07 2024-11-12 亘喜生物科技（上海）有限公司 用于免疫疗法的组合物和方法
HUE068630T2 (hu) 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
EP3894011B1 (en) 2018-12-11 2025-09-17 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
BR112021012172A2 (pt) 2018-12-12 2021-08-31 Kite Pharma, Inc. Receptores de antígenos quiméricos e de célula t e métodos de uso
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
PH12021551619A1 (en) * 2019-01-06 2022-05-23 Abintus Bio Inc Car t cell methods and constructs
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2020219046A1 (en) 2019-02-04 2021-08-19 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009744A (es) 2019-02-15 2021-11-12 Univ Southern California Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados.
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
SG11202107825WA (en) 2019-02-25 2021-09-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
TW202045547A (zh) 2019-03-01 2020-12-16 美商艾洛基因醫療公司 靶向ｄｌｌ３的嵌合抗原受體和結合劑
AU2020233284A1 (en) * 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
US20220143087A1 (en) 2019-03-08 2022-05-12 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
EA202192555A1 (ru) 2019-03-19 2021-11-25 Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн Комбинированная терапия для лечения рака
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS COMPRISING THEM
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
BR112021019748A2 (pt) 2019-04-05 2021-12-07 Kymera Therapeutics Inc Degradadores de stat e usos dos mesmos
US20220184129A1 (en) * 2019-04-12 2022-06-16 The Trustees Of The University Of Pennsylvania Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
CA3134308A1 (en) 2019-04-26 2020-10-29 Thomas Charles PERTEL Rituximab-resistant chimeric antigen receptors and uses thereof
AU2020261411B2 (en) 2019-04-26 2025-10-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car T cells
KR20220016083A (ko) 2019-04-30 2022-02-08 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
EA202192975A1 (ru) 2019-04-30 2022-02-01 Криспр Терапьютикс Аг Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CN118593691A (zh) 2019-05-03 2024-09-06 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法
JP7741732B2 (ja) 2019-05-07 2025-09-18 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド Ｂｃｍａを標的とする操作された免疫細胞及びその使用
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
EP3972696A1 (en) 2019-05-22 2022-03-30 Leidos, Inc. Lag3 binding peptides
EP3973072A1 (en) 2019-05-23 2022-03-30 Vogelsang, Matjaz Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
TW202112808A (zh) * 2019-06-05 2021-04-01 日商中外製藥股份有限公司 抗體切斷部位結合分子
US20200384029A1 (en) * 2019-06-07 2020-12-10 The Trustees Of The University Of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
EP3980530A1 (en) 2019-06-07 2022-04-13 Juno Therapeutics, Inc. Automated t cell culture
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP2022537700A (ja) 2019-06-12 2022-08-29 ジュノー セラピューティクス インコーポレイテッド 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法
WO2020257823A2 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
US20220347222A1 (en) 2019-06-24 2022-11-03 The Regents Of The University Of California BCL11B Overexpression to Enhance Human Thymopoiesis and T Cell Function
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
CN114269783B (zh) 2019-07-02 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 结合egfrviii的单克隆抗体及其应用
GB201909573D0 (en) 2019-07-03 2019-08-14 Cancer Research Tech Ltd Modulation of T cell cytotoxicity and related therapy
JPWO2021010326A1 (enExample) 2019-07-12 2021-01-21
EP3999081A1 (en) 2019-07-18 2022-05-25 GPB Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
JP7735249B2 (ja) 2019-07-23 2025-09-08 ムネモ・セラピューティクス Ｓｕｖ３９ｈ１欠損免疫細胞
MX2022000896A (es) 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
JP2022542446A (ja) 2019-07-30 2022-10-03 ユニバーシティー ヘルス ネットワーク Ｍｈｃクラスｉｉ分子及びその使用方法
CN110305849B (zh) * 2019-08-01 2021-03-30 广东万海细胞生物科技有限公司 稳定表达car的t细胞及其制备方法与应用
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
EP4017527A1 (en) 2019-08-22 2022-06-29 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
EP4021485A1 (en) * 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
KR20220073738A (ko) 2019-08-30 2022-06-03 주노 쎄러퓨티크스 인코퍼레이티드 세포 분류를 위한 기계 학습 방법
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
MX2022002578A (es) 2019-09-02 2022-06-02 Inst Curie Inmunoterapia dirigida a peptidos neoantigenicos tumorales.
WO2021046134A1 (en) 2019-09-03 2021-03-11 Allogene Therapeutics, Inc. Methods of preparing t cells for t cell therapy
US20220333132A1 (en) 2019-09-03 2022-10-20 Sana Blotechnology, Inc. Cd24-associated particles and related methods and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4028523A1 (en) 2019-09-09 2022-07-20 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
WO2021051088A1 (en) * 2019-09-13 2021-03-18 Ohio State Innovation Foundation Nk cell immunotherapy compositions, methods of making and methods of using same
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP2023501871A (ja) 2019-09-20 2023-01-20 上海吉倍生物技術有限公司 Ｂｃｍａ標的化抗体及びキメラ抗原受容体
EP4031654A4 (en) * 2019-09-20 2023-11-22 The University of North Carolina at Chapel Hill MODIFIED T CELLS AND METHOD FOR PRODUCING THEREOF
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
KR102685211B1 (ko) * 2019-09-26 2024-07-16 주식회사 헬릭스미스 항-c-Met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
KR102287180B1 (ko) * 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
CN115103910A (zh) 2019-10-03 2022-09-23 工匠开发实验室公司 具有工程化的双引导核酸的crispr系统
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
WO2021081330A1 (en) 2019-10-23 2021-04-29 Kite Pharma, Inc. Anti-idiotypic antigen binding molecules and methods of use thereof
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
CN114929360A (zh) 2019-10-30 2022-08-19 朱诺治疗学有限公司 细胞选择和/或刺激装置及使用方法
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
US20220403002A1 (en) * 2019-11-01 2022-12-22 Kyoto Prefectural Public University Corporation B-cell antibody receptor and use thereof
KR20220122615A (ko) 2019-11-07 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 (ｓ)-3-[4-(4-모르폴린-4-일메틸-벤질옥시)-1-옥소-1,3-디하이드로-이소인돌-2-일]-피페리딘-2,6-디온의 병용
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
IL292934A (en) 2019-11-20 2022-07-01 Gi Cell Inc Composition of medium for t-cell culture and method for culture of t-cells using the same composition of medium
US11591339B2 (en) 2019-11-26 2023-02-28 Ikena Oncology, Inc. Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
AU2020393912B2 (en) 2019-11-26 2025-11-20 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
PH12022551290A1 (en) 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
US20230028050A1 (en) 2019-12-06 2023-01-26 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
IL293393A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
TW202136251A (zh) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak降解劑及其用途
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
JP7088902B2 (ja) * 2019-12-27 2022-06-21 クレージュ メディカル カンパニー，リミテッド キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
KR20220129566A (ko) 2019-12-28 2022-09-23 지피비 싸이언티픽, 인크 입자 및 세포를 처리하기 위한 미세 유체 카트리지
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
CN113150167A (zh) * 2020-01-22 2021-07-23 中国人民解放军总医院第五医学中心 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
WO2021150919A1 (en) 2020-01-23 2021-07-29 The Children's Medical Center Corporation Stroma-free t cell differentiation from human pluripotent stem cells
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
EP4093433A1 (en) 2020-01-24 2022-11-30 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
EP4093753A1 (en) 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
CN115427550A (zh) 2020-01-28 2022-12-02 朱诺治疗学股份有限公司 T细胞转导方法
WO2021155897A1 (en) 2020-02-03 2021-08-12 MVZ Prof. Niendorf Pathologie Hamburg-West GmbH Marker set for the diagnosis and treatment of cancer
BR112022015236A2 (pt) 2020-02-12 2022-09-20 Juno Therapeutics Inc Composições de células t do receptor de antígeno quimérico direcionado a cd19 e métodos e usos das mesmas
AU2021219764A1 (en) 2020-02-12 2022-09-01 Juno Therapeutics, Inc. BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
CA3170345A1 (en) 2020-02-14 2021-08-19 The Johns Hopkins University Methods and materials for assessing nucleic acids
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
JP7781761B2 (ja) 2020-02-27 2025-12-08 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
CN115515685B (zh) 2020-03-03 2025-04-08 皮克医疗公司 Eif4e抑制剂及其用途
CA3170369A1 (en) 2020-03-05 2022-04-14 Michal Shahar Methods and compositions for treating cancer with immune cells
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for producing engineered memory-like nk cells and preparations containing them
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
AU2021248815A1 (en) 2020-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Targeted lipid particles and compositions and uses thereof
EP3892720A1 (en) 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
EP4132542A2 (en) 2020-04-10 2023-02-15 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
WO2021211663A1 (en) * 2020-04-14 2021-10-21 St. Jude Children's Research Hospital, Inc. Chimeric myd88 receptors
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) * 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
WO2021211776A1 (en) 2020-04-15 2021-10-21 California Institute Of Technology Thermal control of t-cell immunotherapy through molecular and physical actuation
GB202005599D0 (en) 2020-04-17 2020-06-03 Univ London Modulation of t cell cytotoxicity and related therapy
CN116157125A (zh) 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合
GB202006254D0 (en) 2020-04-28 2020-06-10 Institute Of Cancer Res Anti-cancer vaccines and related therapy
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
AU2021264550A1 (en) 2020-05-01 2022-11-17 Gilead Sciences, Inc. CD73 inhibiting 2,4-dioxopyrimidine compounds
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
EP4146697A1 (en) 2020-05-05 2023-03-15 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta
US20230212243A1 (en) 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
US20230181641A1 (en) 2020-05-13 2023-06-15 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
WO2021231954A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof
BR112022024027A2 (pt) 2020-05-27 2023-02-07 Antion Biosciences Sa Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
WO2021244654A1 (en) * 2020-06-05 2021-12-09 Nanjing Legend Biotech Co., Ltd. Activation induced cytokine production in immune cells
US20220057381A1 (en) 2020-06-08 2022-02-24 Janssen Biotech, Inc. Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
JP2023530039A (ja) 2020-06-08 2023-07-12 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CN116829581A (zh) * 2020-06-22 2023-09-29 莱蒂恩技术公司 用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
WO2021263227A2 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN116490518A (zh) 2020-07-17 2023-07-25 西穆尔克斯股份有限公司 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
CN116096864A (zh) 2020-07-30 2023-05-09 居里研究所 Socs1缺陷的免疫细胞
AU2021316230A1 (en) 2020-07-31 2023-03-16 Leidos, Inc. LAG3 binding peptides
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230324408A1 (en) 2020-08-05 2023-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
US20230293581A1 (en) 2020-08-13 2023-09-21 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
CN116583607A (zh) 2020-08-13 2023-08-11 耶鲁大学 用于工程改造和选择具有期望表型的car t细胞的组合物和方法
US20220047677A1 (en) 2020-08-14 2022-02-17 Kite Pharma, Inc. Immune cell function
JP2023538906A (ja) 2020-08-17 2023-09-12 バイシクルティーエクス・リミテッド ネクチン－４に特異的な二環コンジュゲート及びその使用
MX2023002041A (es) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para mesotelina.
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
US20230272068A1 (en) 2020-08-21 2023-08-31 12343096 Canada Inc. Modular assembly receptors and uses thereof
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
EP4204545A2 (en) 2020-08-25 2023-07-05 Kite Pharma, Inc. T cells with improved functionality
US20230302135A1 (en) * 2020-08-26 2023-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Hybrid allosteric receptor-engineered stem cells
AU2021361844A1 (en) 2020-10-12 2023-06-15 Leidos, Inc. Immunomodulatory peptides
CN116600816A (zh) * 2020-10-16 2023-08-15 尼昂克技术公司 用于治疗cns感染的poh和瑞德西韦的组合
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
EP4237854A1 (en) 2020-10-28 2023-09-06 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
KR20230104222A (ko) 2020-11-06 2023-07-07 노파르티스 아게 B 세포 악성종양 치료를 위한 항-cd19 작용제 및 b 세포 표적화제 병용 요법
CN116635062A (zh) 2020-11-13 2023-08-22 诺华股份有限公司 使用表达嵌合抗原受体（car）的细胞的组合疗法
IL302728A (en) 2020-11-13 2023-07-01 Catamaran Bio Inc Genetically modified natural killer cells and methods of use thereof
CN112195250A (zh) * 2020-11-20 2021-01-08 山东省医学科学院附属医院 一种qPCR试剂盒及应用
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2023553419A (ja) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド 遺伝子操作細胞およびその使用
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CA3205830A1 (en) 2020-12-24 2022-06-30 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
US20240316199A1 (en) 2020-12-30 2024-09-26 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
KR20230137900A (ko) 2020-12-31 2023-10-05 사나 바이오테크놀로지, 인크. Car-t 활성을 조정하기 위한 방법 및 조성물
AU2022205377A1 (en) 2021-01-08 2023-07-20 Cellanome, Inc. Devices and methods for analyzing biological samples
AU2022205653B2 (en) 2021-01-10 2025-05-22 Kite Pharma, Inc. T cell therapy
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
EP4274901A1 (en) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Her2 single domain antibodies variants and cars thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022161355A1 (en) 2021-01-26 2022-08-04 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
EP4284836A4 (en) * 2021-01-27 2025-01-01 H. Lee Moffitt Cancer Center & Research Institute, Inc. Bi-specific car t cells for b cell malignancies
AU2022212090A1 (en) 2021-01-28 2023-07-06 Allogene Therapeutics, Inc. Methods for transducing immune cells
HUE071594T2 (hu) 2021-01-28 2025-09-28 Regeneron Pharma Készítmények és módszerek a citokinfelszabadulási szindróma kezelésére
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
EP4291235A4 (en) 2021-02-12 2025-01-08 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
US20220265719A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Immunotherapies
WO2022182801A1 (en) 2021-02-25 2022-09-01 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
JP2024509192A (ja) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
CN116940377A (zh) 2021-03-05 2023-10-24 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
KR20240006721A (ko) 2021-03-11 2024-01-15 엥스띠뛰 퀴리 막 형질 전환 네오 안티젠 펩타이드
KR20230155521A (ko) 2021-03-11 2023-11-10 카이트 파마 인코포레이티드 면역 세포 기능의 향상
MX2023010641A (es) 2021-03-11 2024-02-07 Mnemo Therapeutics Peptidos neoantigénicos tumorales y usos de los mismos.
CA3212964A1 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides
KR20230157371A (ko) 2021-03-17 2023-11-16 다이이찌 산쿄 가부시키가이샤 항아세틸콜린 수용체 자기 항체에 대한 키메라 수용체를 코드하는 유전자
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
JP2024512590A (ja) 2021-03-26 2024-03-19 アーセルクス インコーポレイテッド 多機能免疫細胞療法
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
MX2023011370A (es) 2021-03-29 2023-11-24 Juno Therapeutics Inc Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma.
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023020781A2 (pt) 2021-04-09 2023-12-19 Nimbus Clio Inc Moduladores de cbl-b e usos dos mesmos
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4323943A1 (en) 2021-04-16 2024-02-21 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
JP2024514163A (ja) 2021-04-16 2024-03-28 セルジーン コーポレーション Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
IL307673A (en) 2021-04-16 2023-12-01 Ikena Oncology Inc MEK inhibitors and their use
US12337035B2 (en) 2021-04-16 2025-06-24 Kite Pharma, Inc. TACI binding molecules
CN117545492A (zh) 2021-04-22 2024-02-09 贝勒医学院 工程改造具有减少的自相残杀活性的免疫细胞的方法
AU2022261141A1 (en) * 2021-04-23 2023-11-30 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
EP4330377A2 (en) 2021-04-27 2024-03-06 Takeda Pharmaceutical Company Limited Recombinant antigen presenting cells
JP2024515793A (ja) 2021-04-27 2024-04-10 ノバルティス アーゲー ウイルスベクター生産システム
IL308231A (en) 2021-05-04 2024-01-01 Regeneron Pharma MAGE-44-specific chimeric antigen receptors and their uses
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
JP2024517956A (ja) 2021-05-14 2024-04-23 カイト ファーマ インコーポレイテッド キメラ抗原受容体ｔ細胞療法
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
EP4340851A1 (en) 2021-05-19 2024-03-27 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
AU2022282266B2 (en) 2021-05-24 2025-09-18 Kite Pharma, Inc. NKG2D-based chimeric antigen receptor
WO2022251434A1 (en) * 2021-05-26 2022-12-01 Emory University Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy
CA3216346A1 (en) 2021-05-27 2022-12-01 Edward Rebar Hypoimmunogenic cells comprising engineered hla-e or hla-g
IL308836A (en) 2021-05-28 2024-01-01 Sana Biotechnology Inc Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
KR20240049794A (ko) 2021-06-07 2024-04-17 프로비던스 헬스 앤드 서비시즈 - 오레곤 Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
AU2022291365A1 (en) 2021-06-08 2024-01-18 Kite Pharma, Inc. Gpc3 binding molecules
WO2022266538A2 (en) 2021-06-18 2022-12-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
CA3223074A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen specific t cells
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
PE20242071A1 (es) 2021-06-23 2024-10-18 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
US20230027004A1 (en) 2021-07-01 2023-01-26 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
KR20240028503A (ko) 2021-07-02 2024-03-05 카이트 파마 인코포레이티드 세포 요법 응용 분야에 사용되는 유전자 작제물의 유전자 산물에서 변이체를 식별하는 방법
US20240368145A1 (en) 2021-07-09 2024-11-07 Immunic Ag Methods for treating cancer
JP2024530403A (ja) 2021-07-14 2024-08-21 サナ バイオテクノロジー，インコーポレイテッド 低免疫原性細胞におけるｙ染色体連鎖抗原の変化した発現
CA3224974A1 (en) * 2021-07-16 2023-01-19 Albert Ruzo Matias Polycistronic vectors for cell-based therapies
US20240325534A1 (en) * 2021-07-19 2024-10-03 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
TW202313665A (zh) 2021-07-30 2023-04-01 美商凱特製藥公司 細胞療法誘導之毒性的監測及管理
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023014922A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023019128A1 (en) * 2021-08-09 2023-02-16 The Trustees Of The University Of Pennyslvania Optimizing t cell differentiation state with micrornas
MX2024001208A (es) 2021-08-11 2024-04-22 Sana Biotechnology Inc Celulas primarias geneticamente modificadas para terapia celular alogenica.
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
EP4384544A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
US20250295693A1 (en) 2021-08-18 2025-09-25 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
AR126838A1 (es) 2021-08-20 2023-11-22 Novartis Ag Métodos para preparar células que expresan receptores de antígeno quiméricos
JP2024531446A (ja) 2021-08-24 2024-08-29 エコール ポリテクニーク フェデラル デ ローザンヌ （イーピーエフエル） 癌免疫療法の増強のためのｉｌ－１０発現細胞
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CA3232833A1 (en) 2021-09-27 2023-03-30 Kathleen Mcginness Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
CR20240195A (es) 2021-10-14 2024-06-20 Arsenal Biosciences Inc Células inmunitarias que tienen arnhc coexpresados y sistemas de compuerta lógica
AU2022373657A1 (en) 2021-10-18 2024-05-16 Kite Pharma, Inc. Signaling domains for chimeric antigen receptors
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
AR127505A1 (es) 2021-10-29 2024-01-31 Kymera Therapeutics Inc Degradadores irak-4 y síntesis de los mismos
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
KR20240112994A (ko) 2021-11-03 2024-07-19 셀진 코포레이션 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
US20250354167A1 (en) 2021-12-09 2025-11-20 Zygosity Limited Vector
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR102809807B1 (ko) * 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022422147A1 (en) 2021-12-23 2024-07-04 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
IL313935A (en) 2021-12-30 2024-08-01 Tr1X Inc CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
US20250154503A1 (en) 2022-01-14 2025-05-15 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
US20230227779A1 (en) 2022-01-19 2023-07-20 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
AU2023209589A1 (en) 2022-01-21 2024-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Modulation of suv39h1 expression by rnas
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023154890A2 (en) * 2022-02-11 2023-08-17 Fred Hutchinson Cancer Center Chimeric antigen receptors binding steap1
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
CA3259019A1 (en) 2022-02-15 2023-08-24 Kite Pharma Inc PREDICTION OF ADVERSE EVENTS FROM IMMUNOTHERAPY
JP2025508720A (ja) 2022-02-17 2025-04-10 サナ バイオテクノロジー，インコーポレイテッド 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照
JP2025508783A (ja) 2022-02-22 2025-04-10 ジュノー セラピューティクス インコーポレイテッド プロテイナーゼ３（ｐｒ３）キメラ自己抗体受容体ｔ細胞ならびに関連する方法および使用
TW202340457A (zh) 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
EP4486881A1 (en) 2022-03-01 2025-01-08 Celyntra Therapeutics SA Composition and methods for transgene insertion
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
EP4490191A1 (en) 2022-03-08 2025-01-15 Alentis Therapeutics AG Use of anti-claudin-1 antibodies to increase t cell availability
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
US20250228940A1 (en) 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences Inc Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
US20250195573A1 (en) 2022-03-18 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Genetically engineered t-cell co-receptors and methods of use thereof
CN119031937A (zh) 2022-03-24 2024-11-26 吉利德科学公司 用于治疗表达Trop-2的癌症的联合疗法
US20250302930A1 (en) 2022-03-24 2025-10-02 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
GB202204386D0 (en) 2022-03-28 2022-05-11 Cambridge Entpr Ltd Engineered immune cell platform
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20250304913A1 (en) 2022-04-06 2025-10-02 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250161360A1 (en) 2022-05-10 2025-05-22 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230272A1 (en) 2022-05-27 2023-11-30 Kite Pharma, Inc. Non-viral delivery of cell therapy constructs
CA3254198A1 (en) 2022-05-27 2023-11-30 Kite Pharma Inc COMPOSITIONS AND PROCESSES FOR PREPARING MODIFIED LYMPHOCYTES FOR CELL THERAPY
CN119343444A (zh) 2022-06-09 2025-01-21 凯德药业股份有限公司 制备用于细胞疗法的淋巴细胞的方法
AU2023283773A1 (en) 2022-06-10 2024-12-19 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2023242343A1 (en) 2022-06-15 2023-12-21 Immunoscape Pte. Ltd. Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
EP4547230A1 (en) 2022-06-29 2025-05-07 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
JP2025525439A (ja) 2022-06-30 2025-08-05 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
JP2025522762A (ja) 2022-07-01 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN119923410A (zh) 2022-07-28 2025-05-02 莱蒂恩技术公司 用于治疗实体瘤的嵌合抗原受体治疗
CA3263154A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
CA3263151A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Ltd HETEROARYL-CARBOXAMIDE AND ASSOCIATED GPR84 ANTAGONISTS AND THEIR USES
IL318710A (en) 2022-08-02 2025-03-01 Univ Hokkaido Nat Univ Corp Methods for improving cellular therapy with organelle complexes
EP4565564A1 (en) 2022-08-02 2025-06-11 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
CN119816590A (zh) 2022-08-10 2025-04-11 武田药品工业株式会社 低免疫原性的经修饰细胞
EP4572787A1 (en) 2022-08-19 2025-06-25 SOTIO Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
EP4577234A1 (en) 2022-08-26 2025-07-02 Kite Pharma, Inc. Improving immune cell function
KR20250084921A (ko) 2022-08-26 2025-06-11 주노 쎄러퓨티크스 인코퍼레이티드 델타-유사 리간드 3 (dll3)에 특이적인 항체 및 키메라 항원 수용체
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
CN119907680A (zh) 2022-09-15 2025-04-29 诺华股份有限公司 使用嵌合抗原受体疗法的自身免疫性障碍的治疗
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
CN116063560A (zh) * 2022-09-21 2023-05-05 东莞市东南部中心医院 一种sh Blimp-1 CAR-T细胞的构建及应用
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
AU2023353989A1 (en) 2022-09-30 2025-02-27 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), cells expressing the cars and related methods
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
CN120051287A (zh) 2022-10-28 2025-05-27 凯德药业股份有限公司 工程化淋巴细胞的加速施用
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
KR20250097844A (ko) 2022-10-28 2025-06-30 카이트 파마 인코포레이티드 면역요법의 효능 향상 및 지속적인 반응
US20240158869A1 (en) 2022-10-28 2024-05-16 Kite Pharma, Inc. Factors for optimizing immunotherapy
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024097315A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
KR20250068756A (ko) 2022-11-14 2025-05-16 카리부 바이오사이언시스 인코포레이티드 항-cll-1 키메라 항원 수용체, 조작된 세포 및 관련 방법
WO2024107029A1 (ko) 2022-11-18 2024-05-23 서울대학교산학협력단 Ctla-4 변이체 및 키메라 항원수용체를 이용한 이중 유전자 이입 면역세포 및 이의 용도
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
CN120615013A (zh) 2022-12-01 2025-09-09 世代生物公司 用于细胞靶向的隐形脂质纳米颗粒组合物
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
TW202502363A (zh) 2023-02-28 2025-01-16 美商奇諾治療有限公司 用於治療全身性自體免疫疾病之細胞療法
AU2024233625A1 (en) 2023-03-03 2025-09-18 Arsenal Biosciences, Inc. Systems targeting psma and ca9
AU2024233069A1 (en) 2023-03-09 2025-09-11 Kite Pharma, Inc. Antigen binding molecules and methods of use
TW202436346A (zh) 2023-03-13 2024-09-16 美商亞森諾生物科學公司 合成路徑活化劑
US20240309428A1 (en) 2023-03-17 2024-09-19 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy
WO2024194471A1 (en) 2023-03-23 2024-09-26 Alentis Therapeutics Ag Biomarker for cancer treatment using anti-claudin-1 antibodies
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
KR20250131823A (ko) 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
CN120882754A (zh) 2023-04-07 2025-10-31 瑞泽恩制药公司 用淋巴毒素β受体激动剂治疗癌症的方法
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
TW202444898A (zh) 2023-04-21 2024-11-16 美商凱特製藥公司 免疫排斥之風險降低的同種異體治療性細胞
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN121038806A (zh) 2023-04-25 2025-11-28 阿森纳生物科学公司 用于转录调控的新颖受体
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024224359A1 (en) 2023-04-27 2024-10-31 Takeda Pharmaceutical Company Limited Method for expanding cd56+/cd3- cells
WO2024222859A1 (zh) 2023-04-28 2024-10-31 深圳深信生物科技有限公司 经修饰的递送载体及其应用
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024233882A1 (en) 2023-05-11 2024-11-14 Alaya.Bio Inc. Extracellular vesicles for the delivery of payloads to eukaryotic cells
WO2024238656A1 (en) 2023-05-15 2024-11-21 Yale Univeristy Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
WO2024238903A1 (en) * 2023-05-17 2024-11-21 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses within a mammal
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2024243514A1 (en) * 2023-05-25 2024-11-28 Trustees Of Dartmouth College Leveraging photothermal heating for surface processing of active agents
WO2024243511A1 (en) 2023-05-25 2024-11-28 Regeneron Pharmaceuticals, Inc. T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
WO2024259376A2 (en) 2023-06-14 2024-12-19 Arsenal Biosciences, Inc. Non-viral cell engineering
CN120379669A (zh) 2023-06-23 2025-07-25 凯麦拉医疗公司 Irak降解剂及其用途
WO2025007073A2 (en) 2023-06-29 2025-01-02 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025051339A1 (en) 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025059414A1 (en) * 2023-09-15 2025-03-20 Singular Immune, Inc. Composition and method of use recombinant fusion protein to generate car-immune cells
WO2025068803A1 (en) 2023-09-26 2025-04-03 Astrazeneca Ab Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
WO2025072571A1 (en) 2023-09-27 2025-04-03 Cellanome, Inc. Cell culture within microfluidic structures
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025083398A1 (en) 2023-10-16 2025-04-24 Cell Therapy Catapult Limited Co-culture
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025090985A1 (en) * 2023-10-27 2025-05-01 Duke University Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
WO2025096594A2 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
WO2025096305A1 (en) * 2023-10-30 2025-05-08 The Cleveland Clinic Foundation Chimeric antigen receptors with a tip co-stimulatory domain
WO2025096419A1 (en) 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025096517A1 (en) 2023-11-01 2025-05-08 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
TW202526007A (zh) 2023-12-21 2025-07-01 美商凱特製藥公司 用於上調低密度脂蛋白受體（ｌｄｌ－ｒ）表現之系統及方法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025146286A1 (en) 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025151923A1 (en) * 2024-01-17 2025-07-24 Newsouth Innovations Pty Limited Apparatus for production of engineered cells
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US20250297219A1 (en) 2024-02-08 2025-09-25 Kite Pharma, Inc. Methods for generating engineered lymphocytes with enriched t memory stem cells
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025181329A1 (en) 2024-03-01 2025-09-04 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
US20250290154A1 (en) 2024-03-04 2025-09-18 Kite Pharma, Inc. Predictive markers for immunotherapy
WO2025191300A1 (en) 2024-03-12 2025-09-18 Novartis Ag Rapcabtagene autoleucel for use in treating systemic lupus erythematosus
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025191531A1 (en) 2024-03-15 2025-09-18 Takeda Pharmaceutical Company Limited Cd19 targeting car nk cells in treating systemic lupus erythematosus and lupus nephritis
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
WO2025199338A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting slc34a2 and tmprss4 and methods of use thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025231376A1 (en) 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer
WO2025250819A1 (en) 2024-05-31 2025-12-04 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517301A (ja) 1999-11-10 2003-05-27 ザ ユーエービー リサーチ ファウンデイション 造血幹細胞のレンチウイルスベクター形質導入

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4882282A (en) * 1985-08-16 1989-11-21 Immunex Corporation DNA sequences encoding bovine interleukin-2
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ES2096749T3 (es) 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
ATE454449T1 (de) * 1993-09-16 2010-01-15 Univ Indiana Res & Tech Corp Menschlicher rezeptor h4-1bb
PT758394E (pt) 1994-05-02 2003-04-30 Bernd Groner Proteina bifuncional sua preparacao e utilizacao
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
ATE297986T1 (de) 1995-02-24 2005-07-15 Gen Hospital Corp Neuorientierung der zellulären immunität durch rezeptorchimären
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
EP0937095A4 (en) 1996-10-25 1999-12-22 Cell Genesys Inc TARGETED CYTOLYSIS OF CANCER CELLS
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
GB9722779D0 (en) * 1997-10-28 1997-12-24 Isis Innovation Human CD8 as an inhibitor of the cellular immune system
PT1047449E (pt) * 1997-10-28 2004-04-30 Univ British Columbia Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2000063374A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic transmembrane components
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
IL136511A0 (en) 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (de) * 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002088334A1 (en) 2001-04-30 2002-11-07 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP3878522B2 (ja) * 2002-07-18 2007-02-07 株式会社日立製作所 ベンチュリ式燃料供給装置を備えたエンジンの空燃比制御方法及びその方法を備えた燃料制御装置
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
EP1827604B1 (en) 2004-12-10 2019-11-20 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
US7581948B2 (en) * 2005-12-21 2009-09-01 Johns Manville Burner apparatus and methods for making inorganic fibers
US7551486B2 (en) * 2006-05-15 2009-06-23 Apple Inc. Iterative memory cell charging based on reference cell value
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US7448191B2 (en) * 2007-02-14 2008-11-11 Deere & Company Mower deck lift system with transport lock
US20080311098A1 (en) * 2007-02-14 2008-12-18 Lapointe Rejean Compounds and methods for modulating the immune response against antigens
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
US8450112B2 (en) * 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PL3006459T3 (pl) * 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
CN101348525B (zh) * 2008-08-28 2011-11-16 南京医科大学 抗血吸虫单克隆抗体np11-4单链抗体及其制备方法、应用
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
US8679492B2 (en) * 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9493740B2 (en) 2010-09-08 2016-11-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered GD2-specific T cells
CA2816379A1 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3102782A1 (en) 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EP2694553B1 (en) 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP2755487B1 (en) 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EP2768863B1 (en) 2011-10-20 2017-09-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd22 chimeric antigen receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517301A (ja) 1999-11-10 2003-05-27 ザ ユーエービー リサーチ ファウンデイション 造血幹細胞のレンチウイルスベクター形質導入

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Leukemia, Vol.18, pp.676-684 (2004)
Molecular Immunology, Vol.34, No.16-17, pp.1157-1165 (1997)
Molecular Therapy, Vol.17, No.8, pp.1453-1464 (2009.08.)
NCBI Reference Sequence: NM_000734.3 (2009.12.07.)

Also Published As

Publication number Publication date
WO2012079000A4 (en) 2012-08-23
EP3214091A1 (en) 2017-09-06
HUE036872T2 (hu) 2018-08-28
AU2020200767C1 (en) 2025-04-24
MA34813B1 (fr) 2014-01-02
KR102417796B9 (ko) 2024-03-06
NI201300051A (es) 2014-01-07
US20160159907A1 (en) 2016-06-09
LTPA2019502I1 (lt) 2019-03-12
JP5947311B2 (ja) 2016-07-06
EP3660029A1 (en) 2020-06-03
ES2641870T3 (es) 2017-11-14
CN110452882A (zh) 2019-11-15
KR20230133410A (ko) 2023-09-19
FR19C1006I2 (fr) 2020-03-20
KR20200014343A (ko) 2020-02-10
JP2014507118A (ja) 2014-03-27
JP6943933B2 (ja) 2021-10-06
US20160194404A1 (en) 2016-07-07
JP7426361B2 (ja) 2024-02-01
CN103492406A (zh) 2014-01-01
HUS1900006I1 (hu) 2019-04-29
CN108103085A (zh) 2018-06-01
NO2019007I1 (no) 2019-02-15
US20170283775A1 (en) 2017-10-05
AU2017225161C1 (en) 2021-07-29
US9102760B2 (en) 2015-08-11
US8911993B2 (en) 2014-12-16
AP2013006918A0 (en) 2013-06-30
US20150050729A1 (en) 2015-02-19
KR20220101745A (ko) 2022-07-19
EP3214091B1 (en) 2018-10-03
TR201820015T4 (tr) 2019-01-21
ECSP13012739A (es) 2013-10-31
US20130309258A1 (en) 2013-11-21
WO2012079000A1 (en) 2012-06-14
JP2018029594A (ja) 2018-03-01
PL2649086T3 (pl) 2018-03-30
JP2022002516A (ja) 2022-01-11
US9328156B2 (en) 2016-05-03
CN108103085B (zh) 2024-10-08
AU2017225161B2 (en) 2019-11-21
CL2013001645A1 (es) 2014-02-14
SG10201510092QA (en) 2016-01-28
US9540445B2 (en) 2017-01-10
CA2820681C (en) 2018-10-23
US20160208012A1 (en) 2016-07-21
HUS1900007I1 (hu) 2019-04-29
EP2649086A4 (en) 2014-12-31
ZA201304470B (en) 2014-08-27
LTC2649086I2 (lt) 2020-12-28
LT3214091T (lt) 2018-12-10
MX385933B (es) 2025-03-18
SI2649086T1 (en) 2018-01-31
BR112013014265A2 (pt) 2017-12-19
AU2020200767A1 (en) 2020-02-27
DK3214091T3 (en) 2019-01-07
JP2018029595A (ja) 2018-03-01
PT3214091T (pt) 2019-01-11
US20130287748A1 (en) 2013-10-31
JP6588060B2 (ja) 2019-10-09
PT2649086T (pt) 2017-10-19
BR112013014265B8 (pt) 2023-12-19
NZ612512A (en) 2015-03-27
JP2024056708A (ja) 2024-04-23
US9101584B2 (en) 2015-08-11
FR19C1006I1 (enExample) 2019-04-05
US9102761B2 (en) 2015-08-11
NO2019006I1 (no) 2019-02-15
AU2017203087B2 (en) 2019-06-20
CY2019008I1 (el) 2019-11-27
DOP2013000128A (es) 2014-03-16
NL300967I2 (nl) 2019-08-20
EA035484B1 (ru) 2020-06-23
MY169644A (en) 2019-04-24
CN106220739A (zh) 2016-12-14
SG190997A1 (en) 2013-07-31
US20180258391A1 (en) 2018-09-13
HK1253052A1 (en) 2019-06-06
JP2016174607A (ja) 2016-10-06
KR102062407B1 (ko) 2020-01-03
LTPA2019503I1 (lt) 2019-03-12
US9481728B2 (en) 2016-11-01
LUC00104I1 (enExample) 2019-02-21
EP2649086A1 (en) 2013-10-16
JP6293194B2 (ja) 2018-03-14
LUC00104I2 (enExample) 2019-12-27
BR122021026173B1 (pt) 2023-12-05
US8916381B1 (en) 2014-12-23
CA2820681A1 (en) 2012-06-14
JP6588514B2 (ja) 2019-10-09
HK1243082B (en) 2019-09-13
US9499629B2 (en) 2016-11-22
HRP20182202T1 (hr) 2019-03-08
KR102243575B1 (ko) 2021-04-22
KR20130124521A (ko) 2013-11-14
US8906682B2 (en) 2014-12-09
US20140106449A1 (en) 2014-04-17
CR20130269A (es) 2013-09-03
US20150118202A1 (en) 2015-04-30
US20140370017A1 (en) 2014-12-18
NL300967I1 (nl) 2019-02-20
MX347078B (es) 2017-04-10
US20150099299A1 (en) 2015-04-09
MY191313A (en) 2022-06-15
KR20210059762A (ko) 2021-05-25
US9518123B2 (en) 2016-12-13
DK2649086T3 (en) 2017-09-18
AU2022201895A1 (en) 2022-04-07
KR102243575B9 (ko) 2023-05-24
CN107699585A (zh) 2018-02-16
AU2011338200A1 (en) 2013-07-04
HRP20171577T1 (hr) 2017-12-01
AU2011338200B2 (en) 2017-02-23
US20130288368A1 (en) 2013-10-31
GT201300150A (es) 2014-06-10
RS58100B1 (sr) 2019-02-28
IL226694B (en) 2020-10-29
PL3214091T3 (pl) 2019-03-29
US9464140B2 (en) 2016-10-11
CN103492406B (zh) 2022-07-26
CY2019007I2 (el) 2019-11-27
AU2017225161A1 (en) 2017-11-09
PE20140178A1 (es) 2014-02-20
RS56453B1 (sr) 2018-01-31
JP2020022456A (ja) 2020-02-13
BR112013014265B1 (pt) 2023-05-16
EA201790175A1 (ru) 2017-09-29
MX2020005143A (es) 2020-08-17
ES2700966T3 (es) 2019-02-20
SI3214091T1 (sl) 2019-02-28
AU2020200767B2 (en) 2021-12-23
BR112013014265A8 (pt) 2018-04-17
CO6801633A2 (es) 2013-11-29
LT2649086T (lt) 2017-11-10
US20150093822A1 (en) 2015-04-02
EP3305798A1 (en) 2018-04-11
US20160130355A1 (en) 2016-05-12
MX2013006570A (es) 2013-08-26
EA027153B1 (ru) 2017-06-30
EA201390847A1 (ru) 2013-12-30
BR122021026169B1 (pt) 2023-12-12
EP2649086B1 (en) 2017-07-19
HUE042207T2 (hu) 2019-06-28
AU2017203087A1 (en) 2017-06-08
US8975071B1 (en) 2015-03-10
CY2019007I1 (el) 2019-11-27
PH12013501201A1 (en) 2013-07-29
CY1119760T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
KR102417796B1 (ko) 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
US12350334B2 (en) Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
CN114656570B (zh) 包含nkg2d结构域的多特异性嵌合受体和其使用方法
KR20140004174A (ko) 암 치료를 위한 조성물 및 방법
KR20250175001A (ko) 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210416

Application number text: 1020197038214

Filing date: 20191224

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210517

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220401

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220701

Application number text: 1020197038214

Filing date: 20191224

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220701

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220704

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PZ0301 Request for patent revocation
PZ0701 Maintenance of registration after request for patent revocation

Comment text: Written Transmittal of Certified Copy of Decision

Patent event code: PZ07011R01D

Patent event date: 20240215

PZ1301 Decision on request for patent revocation

Comment text: Decision on Revocation (Decision on Request for Revocation)

Patent event code: PZ13011R01D

Patent event date: 20240215

Z072 Maintenance of patent after cancellation proceedings: certified copy of decision transmitted [new post grant opposition system as of 20170301]
Z131 Decision taken on request for patent cancellation [new post grant opposition system as of 20170301]
PG1701 Publication of correction

Publication date: 20240306